Medical Technology: What Changing Venture Capital Investments Signal

The market for medical devices historically has been dominated by big-ticket “physician preference items.” Changes in physician payment and organization are reducing the demand for these cost-increasing innovations, and redirecting the flow of investment capital.

January 9, 2017

Germany’s Model For Drug Price Regulation Could Work In The US

If the U.S. cares to examine national models for reducing drug prices, Germany's AMNOG should top the list.

December 29, 2016

The Demise of the Part B Demo: Doom For Value-Based Payment?

Despite widespread, bipartisan agreement that we should be paying for value, even with respect to drugs, the uproar over Part B shows there remains strong resistance to specific policies that attempt to move towards that goal.

December 27, 2016

The Current 21st Century Cures Legislation Is Still A Bad Deal For Patients

We believe the bill’s potential benefits and modestly enhanced funding for scientific advancement are far outweighed by the increased risk of patient harm, and added pressure on the FDA to rush new products to market without adequate evidence.

November 30, 2016

Divorcing Reimbursement From Real-World Prices: Medicare Still Uses 2003 AWPs For Some Drugs

About two-to-three dozen durable medical equipment infusion drugs were exempted from the switch to average sales price. The consequences have been well documented in several OIG reports. This post examines these issues and suggests a path forward for policymakers.

November 21, 2016

Regulatory, Legal Uncertainties Are Barriers To Value-Based Agreements For Drugs

We conducted two-part double-blinded interviews with a group of five stakeholders regarding their experience with value-based agreements.

November 4, 2016

The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs

Using new data released by CMS, we consider both the ongoing impact of hepatitis C drugs for Part D and the broader implications for Medicare of new high-priced drugs entering the market.

November 3, 2016

California’s Proposition 61: Will Direct Democracy Impact Prescription-Drug Pricing?

Even in this unconventional election season, California politics has generated little national interest, but one of the initiatives on this year’s California ballot because may have important implications for drug pricing and policy nationwide.

November 1, 2016

The FDA’s Controversial Duchenne Drug Approval And The Moral Impulse To Rescue

What can we learn from the Food and Drug Administration’s controversial approval of the first drug for Duchenne Muscular Dystrophy (DMD)?

October 25, 2016

Encouraging Integrative, Non-opioid Approaches To Pain: A Policy Agenda

Policy changes are urgently needed to provide better care for patients with chronic pain, and in this post, we outline three feasible policy initiatives.

October 4, 2016